作者
Ming-Ming He,Zhiqiang Wang,Jin Lu,Yuxian Bai,Teng Mao,Jun Wang,Qing-Xia Fan,X.-C. Zhang,Kuaile Zhao,Zhendong Chen,Shegan Gao,Jiancheng Li,Zhichao Fu,Kangsheng Gu,Zhihua Liu,Lin Wu,Xiaodong Zhang,Jifeng Feng,Zuoxing Niu,Yi Ba,Helong Zhang,Ying Liu,Li Zhang,Xuhong Min,Jing Huang,Ying Cheng,Dong Wang,Zhen Sheng,Wanqin Zeng,Song Li,Rui‐Hua Xu,Hui Luo
摘要
The interim analysis of the randomized phase 3 ESCORT-1st study demonstrated significantly longer overall survival (OS) and progression-free survival (PFS) for camrelizumab-chemotherapy than placebo-chemotherapy in untreated advanced/metastatic esophageal squamous cell carcinoma (ESCC). Here, we present the final analysis of this study and investigate potential indicators associated with OS.
爱静静
zzzyyy
Singularity
乐乐乐乐乐乐
浅尝离白
8R60d8
shinysparrow
kento
愤怒的豆腐人
景辣条
寻道图强
竹筏过海
YifanWang
jyy
研友_ZAVbe8
鬼见愁
Ava
睡觉晒太阳
徐叽钰
不配.
皖公网安备34019202002308
